Statement from the Irish Cancer Society on AstraZeneca vaccine deferral
In light of the decision taken by the NIAC, to defer the administration of the AZ vaccine while further information is gathered by the European Medicines Agency (EMA) Rachel Morrogh, Director of Advocacy said:
"The Irish Cancer Society hopes that this review is swift and conclusive, and that the outcome provides assurance and confidence to anyone awaiting vaccination.
During this pause it is essential that patients in Cohorts 4,5 & 7 are identified and communicated with regarding their upcoming vaccinations.
This could help accelerate the vaccination of these groups over the upcoming weeks and ensure those who are most of risk of serious illness as a result of COVID 19 are protected.
Once the NIAC has reviewed the evidence from the EMA, timelines regarding vaccination for medically vulnerable groups must be clearly communicated."